
Durvalumab Plus Tremelimumab and Trastuzumab Yields Clinical Activity in Trastuzumab-Resistant HER2+ Breast Cancer
Treatment with the combination of durvalumab (Imfinzi), tremelimumab (Imjudo), and trastuzumab (Herceptin) produced clinical activity in patients with advanced HER2-positive breast cancer that was resistant to trastuzumab, according to data from the phase …